

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5278812

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION	08/30/2018
RECEIVING PARTY DATA	
Name:	OLIX PHARMACEUTICALS, INC.
Street Address:	1014, GWANGGYO ACE TOWER 1,
Internal Address:	17, DAEHAK 4-RO, YEONGTONG-GU, SUWON-SI
City:	GYEONGGI-DO
State/Country:	KOREA, REPUBLIC OF
Postal Code:	16226
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	9637742
Application Number:	15474615
CORRESPONDENCE DATA	
Fax Number:	(202)739-3001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-739-3000
Email:	patents@morganlewis.com, amanda.mcintyre@morganlewis.com
Correspondent Name:	MORGAN, LEWIS, & BOCKIUS LLP (B0)
Address Line 1:	1111 PENNSYLVANIA AVENUE, NW​
Address Line 4:	WASHINGTON, D.C. 20004-2541
ATTORNEY DOCKET NUMBER:	OLX-005/OLX-005C1/116825-
NAME OF SUBMITTER:	INNA DAHLIN
SIGNATURE:	/Inna Dahlin/
DATE SIGNED:	12/12/2018
Total Attachments: 4	
source=OLX-005_OLX-005C1 University to Company Assignment_Signed#page1.tif	
source=OLX-005_OLX-005C1 University to Company Assignment_Signed#page2.tif	
source=OLX-005_OLX-005C1 University to Company Assignment_Signed#page3.tif	

**PATENT APPLICATION
Company-to-Company Assignment**

For good and valuable consideration, the receipt of which is hereby acknowledged, Sungkyunkwan University Foundation for Corporate Collaboration, an entity of the Republic of Korea, which has the full and exclusive right to certain inventions for which patents have been granted or patent applications are pending, in various jurisdictions. These patents and patent applications are provided in the attached **APPENDIX A**.

Does hereby sell, assign and transfer to OliX Pharmaceuticals, Inc., a corporation having a place of business at 1014, Gwanggyo Ace Tower 1, 17, Daehak 4-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16226, Republic of Korea, its successors, assigns, and legal representatives, the full and exclusive right to said inventions and said patents and patent applications and to any and all inventions described in said inventions and said patents and patent applications and to any and all inventions described in said patents and patent applications for the United States, and its territorial possessions, and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor in the United States and its territorial possessions; and in and to any and all provisionals, continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, and all other applications for Letters Patent relating thereto which have been or shall be filed in the United States and its territorial possession, and all rights, together with all priority rights, under any of the international conventions, unions, agreements, act, and treaties, including all future conventions, unions, agreements, acts, and treaties;

Agree that OliX Pharmaceuticals, Inc., hereinafter referred to as Assignee, may apply for and receive Letters Patent for said inventions, hereinafter referred to as said inventions, in its own name, in the United States, and its territorial possessions; and that, when requested to carry out in good faith the intent and purpose of this assignment, at the expense of said Assignee, its successors, assigns and legal representatives, the undersigned will execute all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, execute all rightful oaths, declarations, assignments, powers of attorney and other papers, testify in any legal or quasi legal proceedings; communicate to said Assignee, its successors, assigns or legal representatives all facts known to the undersigned relating to said invention and the history thereof; and generally do everything possible which said Assignee, its successors, assigns, or legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said invention and for vesting title to said invention and all patents and applications for patents on said invention in said Assignee, successors, assigns, or legal representatives; and

Covenant with said Assignee, its successors, assigns, or legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same has herein expressed is possessed by the undersigned.

Assignor hereby grants the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

MORGAN, LEWIS & BOCKIUS LLP

Patent Assignment

IN THE TESTIMONY WHEREOF we have hereunto set our signatures on the date indicated below.

Signature: *Seong Gee Ho*

SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION

Name: Seong Gee Ho

Date: August 30, 2018

Signature: *Park Bo Bae*

WITNESS

Name: Park Bo Bae

Date: August 30, 2018

Patent Assignment

Signature: 

OLIX PHARMACEUTICALS, INC.

Name and Title: DK Lee, Ph.D., Chief Executive Officer

Date: September 3, 2018

Signature:

WITNESS

Name:

Date:

APPENDIX A

Title	Country	Patent Appn. No.	Patent No.
NUCLEIC ACID MOLECULES INDUCING RNA INTERFERENCE, AND USES THEREOF	US	13/880,670	9,637,742
NUCLEIC ACID MOLECULES INDUCING RNA INTERFERENCE, AND USES THEREOF	US	15/474,615	N/A